Search
siltuximab (Sylvant)
Indications:
- treatment of Castleman's disease
Contraindications:
- HIV1
- HHV-8
Mechanism of action:
- anti-IL-6 chimeric human-mouse monoclonal antibody
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
hematologic agent
pharmaceutical monoclonal antibody
References
- American Cancer Society. April 29, 2014
FDA Approves Sylvant (Siltuximab) for Castleman Disease
http://www.cancer.org/cancer/news/fda-approves-sylvant-siltuximab-for-castleman-disease
- Wikipedia: Siltuximab
http://en.wikipedia.org/wiki/Siltuximab
- Chustecka Z
Medscape: April 24, 2014
Siltuximab: First-Ever Drug for Castleman's Disease
http://www.medscape.com/viewarticle/824072